alexa Gastric Cancer Therapy By Targeting Erythroid Proteins
ISSN: 2153-0645

Journal of Pharmacogenomics & Pharmacoproteomics
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Share This Page

Additional Info

Loading
Loading Please wait..
 

2nd International Conference on Predictive, Preventive and Personalized Medicine & Molecular Diagnostics
November 03-05, 2014 Embassy Suites Las Vegas, USA

Guo-Hui Fu
ScientificTracks Abstracts: J Pharmacogenomics Pharmacoproteomics
DOI: 10.4172/2153-0645.S1.002
Abstract
Epidemiological studies have shown that gastric cancer (GC) is the fourth most common cancer and remains the second most common cause of cancer related death in the world. Due to limitations of the surgery treatment and chemotherapeutic regimens on the overall survival in patients with GC, more and more patients are resorting to molecular diagnosis and biological treatment. Our group revealed that hematopoietic stem cells can be planted in the gastric mucosa and then differentiated into gastric epithelial cells via suppressing innate erythroid proteins and simultaneously inducing the de novo expression of epithelial proteins. Erythroid protein such as band 3 was normally silenced at the protein level at gastric mucosa but was induced under the precancer condition such as HP infection or chronic atrophic gastritis, indicating the expression of erythroid proteins is a key event during the malignant transformation of hematopoietic stem cells at gastric mucosa. We also demonstrated that the expression of erythroid proteins is closely correlated with human GC progression by interrupting the cell cycle regulation and inhibiting the gastric acid secretion. Therefore, the erythroid proteins are the molecular markers for GC diagnosis especially for the poorly-differentiated type of GC. Our group further revealed that gastrin treatment lessened the malignancy of poorly differentiated GC cells by suppressing erythroid protein expression, promoting acid secretion and inactivating Wnt/β-catenin pathway. In addition, co-treatment of gastrin and trastuzumab (HER2-targeted drug for GC) synergistically inhibited the HER2-negative cells. The results provided new markers for GC diagnosis and broaden the therapeutic range of trastuzumab in GC.
Biography
Guo-Hui Fu has completed her MD at the age of 20 from Jiamusi Medical College, China and then completed PhD from Harbin Medical University, China and postdoctoral studies from Kyushu University school of Medicine, Japan. She is the Dean and Professor of Pathology Center, Shanghai Jiao Tong University School of Medicine. She has published more than 81 papers in reputed journals and has been serving as an editorial board member of repute.
image PDF   |   image HTML
 

Relevant Topics

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords